South Korea
· Delayed Price · Currency is KRW Ensol Biosciences Statistics
Total Valuation
Ensol Biosciences has a market cap or net worth of KRW 53.60 billion.
| Market Cap | 53.60B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Ensol Biosciences has 8.62 million shares outstanding.
| Shares Outstanding | 8.62M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 24.28% |
| Owned by Institutions (%) | 5.36% |
| Float | 5.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 97.11 |
| PB Ratio | 7.95 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.01, with a Debt / Equity ratio of 0.46.
| Current Ratio | 9.01 |
| Quick Ratio | 8.46 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -2,544.54 |
Financial Efficiency
Return on equity (ROE) is -59.14% and return on invested capital (ROIC) is -35.28%.
| Return on Equity (ROE) | -59.14% |
| Return on Assets (ROA) | -31.45% |
| Return on Capital (ROIC) | -35.28% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.17% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -48.17% |
| 50-Day Moving Average | 6,090.60 |
| 200-Day Moving Average | 5,519.25 |
| Relative Strength Index (RSI) | 52.40 |
| Average Volume (20 Days) | 12,681 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ensol Biosciences had revenue of KRW 537.46 million and -5.40 billion in losses. Loss per share was -644.00.
| Revenue | 537.46M |
| Gross Profit | 153.05M |
| Operating Income | -5.17B |
| Pretax Income | -5.40B |
| Net Income | -5.40B |
| EBITDA | -4.77B |
| EBIT | -5.17B |
| Loss Per Share | -644.00 |
Balance Sheet
The company has 2.62 billion in cash and 30.00 million in debt, giving a net cash position of 2.59 billion or 300.81 per share.
| Cash & Cash Equivalents | 2.62B |
| Total Debt | 30.00M |
| Net Cash | 2.59B |
| Net Cash Per Share | 300.81 |
| Equity (Book Value) | 6.56B |
| Book Value Per Share | 782.26 |
| Working Capital | 2.53B |
Cash Flow
In the last 12 months, operating cash flow was -4.65 billion and capital expenditures -142.78 million, giving a free cash flow of -4.80 billion.
| Operating Cash Flow | -4.65B |
| Capital Expenditures | -142.78M |
| Free Cash Flow | -4.80B |
| FCF Per Share | -556.54 |
Margins
| Gross Margin | 28.48% |
| Operating Margin | -961.08% |
| Pretax Margin | -1,005.43% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -892.34% |
Dividends & Yields
Ensol Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -10.35% |
| FCF Yield | -8.95% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |